Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

Part of paid clinical trials in Chicago, Illinois.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00588809
Phase
PHASE2
Status
Completed

Conditions

  • Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
  • Adult Acute Promyelocytic Leukemia (M3)
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasms
  • Recurrent Adult Acute Myeloid Leukemia
  • Secondary Acute Myeloid Leukemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase II clinical trial is studying how well selumetinib works in treating patients with recurrent or refractory acute myeloid leukemia. Selumetinib may stop the growth of cancer by blocking some of the enzymes needed for cell growth

Key Dates

Start date
Dec 31, 2007
Status verified
Feb 2013
Primary completion
Apr 30, 2012
Completion
Dec 31, 2012

Study Design

Enrollment
47 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (selumetinib)
    Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Response Rate for Subjects Without FLT3 ITD Mutation [ Time Frame: Up to 52 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Chicago Comprehensive Cancer CenterChicagoIllinois60637-1470-

Find similar trials in Chicago, IL

By research site
University of Chicago Comprehensive Cancer Center· Chicago, IL

Related Studies